**QIBA SPECT BIOMARKER COMMITTEE: Literature Review Task Force**

**Image Acquisition and Technical Considerations**

1. Rajeevan, N., I. G. Zubal, S. Q. Ramsby, S. S. Zoghbi, J. Seibyl and R. B. Innis (1998). "Significance of nonuniform attenuation correction in quantitative brain SPECT imaging." J Nucl Med **39**(10): 1719-1726.
2. Zaknun, J. J., H. Schucktanz and F. Aichner (2007). "Impact of instrumentation on DaTSCAN imaging: how feasible is the concept of cross-systems correction factor?" Q J Nucl Med Mol Imaging **51**(2): 194-203.
3. Bienkiewicz, M., M. Gorska-Chrzastek, J. Siennicki, A. Gajos, A. Bogucki, A. Mochecka-Thoelke, A. Plachcinska and J. Kusmierek (2008). "Impact of CT based attenuation correction on quantitative assessment of DaTSCAN ((123)I-Ioflupane) imaging in diagnosis of extrapyramidal diseases." Nucl Med Rev Cent East Eur **11**(2): 53-58.
4. Seibyl, J., K. Marek and I. G. Zubal (2010). "The role of the core imaging laboratory in multicenter trials." Semin Nucl Med **40**(5): 338-346.
5. Seibyl, J., I. G. Zubal, D. Jennings, K. Marek and P. M. Doraiswamy (2011). "Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies." Expert Rev Neurother **11**(12): 1783-1793.
6. Lange, C., A. Seese, S. Schwarzenbock, K. Steinhoff, B. Umland-Seidler, B. J. Krause, W. Brenner, O. Sabri, J. Kurth, S. Hesse and R. Buchert (2014). "CT-based attenuation correction in I-123-ioflupane SPECT." PLoS One **9**(9): e108328.
7. Lange, C., J. Kurth, A. Seese, S. Schwarzenbock, K. Steinhoff, B. Umland-Seidler, B. J. Krause, W. Brenner, O. Sabri, S. Hesse and R. Buchert (2015). "Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy." Eur Radiol **25**(9): 2709-2717.

**Clinical -Visual Outcomes**

1. Catafau, A. M., E. Tolosa and T. C. U. P. S. S. G. Da (2004). "Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes." Mov Disord **19**(10): 1175-1182.
2. Tolosa, E., T. V. Borght, E. Moreno and T. C. U. P. S. S. G. Da (2007). "Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study." Mov Disord **22**(16): 2346-2351.
3. Clarimon, J., J. Pagonabarraga, C. Paisan-Ruiz, A. Campolongo, B. Pascual-Sedano, J. F. Marti-Masso, A. B. Singleton and J. Kulisevsky (2008). "Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening." Mov Disord **23**(4): 518-523.
4. Vlaar, A. M., T. de Nijs, A. G. Kessels, F. W. Vreeling, A. Winogrodzka, W. H. Mess, S. C. Tromp, M. J. van Kroonenburgh and W. E. Weber (2008). "Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes." Eur Neurol **59**(5): 258-266.
5. Deeb, J., M. Shah, N. Muhammed, R. Gunasekera, K. Gannon, L. J. Findley and C. H. Hawkes (2010). "A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease." QJM **103**(12): 941-952.
6. Sikk, K., P. Taba, S. Haldre, J. Bergquist, D. Nyholm, H. Askmark, T. Danfors, J. Sorensen, L. Thurfjell, R. Raininko, R. Eriksson, R. Flink, C. Farnstrand and S. M. Aquilonius (2010). "Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure." Acta Neurol Scand **121**(4): 237-243.
7. Cummings, J. L., C. Henchcliffe, S. Schaier, T. Simuni, A. Waxman and P. Kemp (2011). "The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration." Brain **134**(Pt 11): 3146-3166.
8. Hauser, R. A. and D. G. Grosset (2012). "[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes." J Neuroimaging **22**(3): 225-230.
9. Kupsch, A. R., N. Bajaj, F. Weiland, A. Tartaglione, S. Klutmann, M. Buitendyk, P. Sherwin, A. Tate and I. D. Grachev (2012). "Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study." J Neurol Neurosurg Psychiatry **83**(6): 620-628.
10. Skorpil, M., V. Soderlund, A. Sundin and P. Svenningsson (2012). "MRI diffusion in Parkinson's disease: using the technique's inherent directional information to study the olfactory bulb and substantia nigra." J Parkinsons Dis **2**(2): 171-180.
11. Kupsch, A., N. Bajaj, F. Weiland, A. Tartaglione, S. Klutmann, R. Copp, P. Sherwin, A. Tate and I. D. Grachev (2013). "Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study." Neurodegener Dis **11**(1): 22-32.
12. Seifert, K. D. and J. I. Wiener (2013). "The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study." Am J Neurodegener Dis **2**(1): 29-34
13. Sierra, M., P. Sanchez-Juan, M. I. Martinez-Rodriguez, I. Gonzalez-Aramburu, I. Garcia-Gorostiaga, M. R. Quirce, E. Palacio, J. M. Carril, J. Berciano, O. Combarros and J. Infante (2013). "Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease." Neurology **80**(7): 621-626.
14. Cummings, J. L., M. J. Fine, I. D. Grachev, C. R. Jarecke, M. K. Johnson, P. H. Kuo, K. L. Schaecher, J. A. Oberdorf, M. Rezak, D. E. Riley and D. Truong (2014). "Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan)." Am J Manag Care **20**(5 Suppl): S97-109.
15. Martinez-Valle Torres, M. D., S. J. Ortega Lozano, M. J. Gomez Heredia, T. Amrani Raissouni, E. Ramos Moreno, P. Moya Espinosa and J. M. Jimenez-Hoyuela (2014). "Longitudinal evaluation using FP-CIT in patients with parkinsonism." Neurologia **29**(6): 327-333.
16. Menendez-Gonzalez, M., F. Tavares, N. Zeidan, J. M. Salas-Pacheco and O. Arias-Carrion (2014). "Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study." Front Aging Neurosci **6**: 56.
17. O'Brien, J. T., W. H. Oertel, I. G. McKeith, D. G. Grosset, Z. Walker, K. Tatsch, E. Tolosa, P. F. Sherwin and I. D. Grachev (2014). "Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials." BMJ Open **4**(7): e005122.
18. Seibyl, J. P., A. Kupsch, J. Booij, D. G. Grosset, D. C. Costa, R. A. Hauser, J. Darcourt, N. Bajaj, Z. Walker, K. Marek, I. McKeith, J. T. O'Brien, K. Tatsch, E. Tolosa, R. A. Dierckx and I. D. Grachev (2014). "Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging." J Nucl Med **55**(8): 1288-1296.
19. Dibble, E. H., D. C. Yoo, R. B. Noto and J. H. Friedman (2015). "Atypical Parkinsonian syndromes with very poor striatal uptake on 123I-ioflupane SPECT imaging." Clin Nucl Med **40**(2): e152-156.
20. Gayed, I., U. Joseph, M. Fanous, D. Wan, M. Schiess, W. Ondo and K. S. Won (2015). "The impact of DaTscan in the diagnosis of Parkinson disease." Clin Nucl Med **40**(5): 390-393.
21. Gomez-Rio, M., M. M. Caballero, J. M. Saez and A. M. Castellanos (2015). "Diagnosis of Neurodegenerative Diseases: the Clinical Approach." Curr Alzheimer Res.
22. Walker, Z., E. Moreno, A. Thomas, F. Inglis, N. Tabet, M. Rainer, G. Pizzolato, A. Padovani and T. D. L. B. P. S. G. Da (2015). "Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study." Br J Psychiatry **206**(2): 145-152.
23. Badoud, S., N. Nicastro, V. Garibotto, P. R. Burkhard and S. Haller (2016). "Distinct spatiotemporal patterns for disease duration and stage in Parkinson's disease." Eur J Nucl Med Mol Imaging **43**(3): 509-516.

**Clinical Quantitativve Outcomes**

1. Innis, R. B., J. P. Seibyl, B. E. Scanley, M. Laruelle, A. Abi-Dargham, E. Wallace, R. M. Baldwin, Y. Zea-Ponce, S. Zoghbi, S. Wang and et al. (1993). "Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease." Proc Natl Acad Sci U S A **90**(24): 11965-11969.
2. Laruelle, M., E. Wallace, J. P. Seibyl, R. M. Baldwin, Y. Zea-Ponce, S. S. Zoghbi, J. L. Neumeyer, D. S. Charney, P. B. Hoffer and R. B. Innis (1994). "Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects." J Cereb Blood Flow Metab **14**(6): 982-994.
3. Seibyl, J. P., E. Wallace, E. O. Smith, M. Stabin, R. M. Baldwin, S. Zoghbi, Y. Zea-Ponce, Y. Gao, W. Y. Zhang, J. L. Neumeyer and et al. (1994). "Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects." J Nucl Med **35**(5): 764-770.
4. Malison, R. T., S. E. Best, E. A. Wallace, E. McCance, M. Laruelle, S. S. Zoghbi, R. M. Baldwin, J. S. Seibyl, P. B. Hoffer, L. H. Price and et al. (1995). "Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts." Psychopharmacology (Berl) **122**(4): 358-362.
5. Malison, R. T., C. J. McDougle, C. H. van Dyck, L. Scahill, R. M. Baldwin, J. P. Seibyl, L. H. Price, J. F. Leckman and R. B. Innis (1995). "[123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder." Am J Psychiatry **152**(9): 1359-1361.
6. Seibyl, J. P., K. L. Marek, D. Quinlan, K. Sheff, S. Zoghbi, Y. Zea-Ponce, R. M. Baldwin, B. Fussell, E. O. Smith, D. S. Charney, C. van Dyck and et al. (1995). "Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease." Ann Neurol **38**(4): 589-598.
7. van Dyck, C. H., J. P. Seibyl, R. T. Malison, M. Laruelle, E. Wallace, S. S. Zoghbi, Y. Zea-Ponce, R. M. Baldwin, D. S. Charney and P. B. Hoffer (1995). "Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT." J Nucl Med **36**(7): 1175-1181.
8. Marek, K. L., J. P. Seibyl, S. S. Zoghbi, Y. Zea-Ponce, R. M. Baldwin, B. Fussell, D. S. Charney, C. van Dyck, P. B. Hoffer and R. P. Innis (1996). "[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease." Neurology **46**(1): 231-237.
9. Seibyl, J. P., M. Laruelle, C. H. van Dyck, E. Wallace, R. M. Baldwin, S. Zoghbi, Y. Zea-Ponce, J. L. Neumeyer, D. S. Charney, P. B. Hoffer and R. B. Innis (1996). "Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters." J Nucl Med **37**(2): 222-228.
10. Seibyl, J. P., K. Marek, K. Sheff, R. M. Baldwin, S. Zoghbi, Y. Zea-Ponce, D. S. Charney, C. H. van Dyck, P. B. Hoffer and R. B. Innis (1997). "Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients." J Nucl Med **38**(9): 1453-1459.
11. Malison, R. T., S. E. Best, C. H. van Dyck, E. F. McCance, E. A. Wallace, M. Laruelle, R. M. Baldwin, J. P. Seibyl, L. H. Price, T. R. Kosten and R. B. Innis (1998). "Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT." Am J Psychiatry **155**(6): 832-834.
12. Malison, R. T., E. McCance, L. L. Carpenter, R. M. Baldwin, J. P. Seibyl, L. H. Price, T. R. Kosten and R. B. Innis (1998). "[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts." Psychopharmacology (Berl) **137**(4): 321-325.
13. Malison, R. T., L. H. Price, R. Berman, C. H. van Dyck, G. H. Pelton, L. Carpenter, G. Sanacora, M. J. Owens, C. B. Nemeroff, N. Rajeevan, R. M. Baldwin, J. P. Seibyl, R. B. Innis and D. S. Charney (1998). "Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography." Biol Psychiatry **44**(11): 1090-1098.
14. Seibyl, J. P., K. Marek, K. Sheff, S. Zoghbi, R. M. Baldwin, D. S. Charney, C. H. van Dyck and R. B. Innis (1998). "Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients." J Nucl Med **39**(9): 1500-1508.
15. Innis, R. B., K. L. Marek, K. Sheff, S. Zoghbi, J. Castronuovo, A. Feigin and J. P. Seibyl (1999). "Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT." Mov Disord **14**(3): 436-442.
16. Jacobsen, L. K., J. K. Staley, R. T. Malison, S. S. Zoghbi, J. P. Seibyl, T. R. Kosten and R. B. Innis (2000). "Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients." Am J Psychiatry **157**(7): 1134-1140.
17. Jacobsen, L. K., J. K. Staley, S. S. Zoghbi, J. P. Seibyl, T. R. Kosten, R. B. Innis and J. Gelernter (2000). "Prediction of dopamine transporter binding availability by genotype: a preliminary report." Am J Psychiatry **157**(10): 1700-1703.
18. Laruelle, M., A. Abi-Dargham, C. van Dyck, R. Gil, D. C. D'Souza, J. Krystal, J. Seibyl, R. Baldwin and R. Innis (2000). "Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT." Biol Psychiatry **47**(5): 371-379.
19. van Dyck, C. H., R. T. Malison, J. P. Seibyl, M. Laruelle, H. Klumpp, S. S. Zoghbi, R. M. Baldwin and R. B. Innis (2000). "Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT." Neurobiol Aging **21**(4): 497-501.
20. Marek, K., R. Innis, C. van Dyck, B. Fussell, M. Early, S. Eberly, D. Oakes and J. Seibyl (2001). "[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression." Neurology **57**(11): 2089-2094.
21. Staley, J. K., S. Krishnan-Sarin, S. Zoghbi, G. Tamagnan, M. Fujita, J. P. Seibyl, P. K. Maciejewski, S. O'Malley and R. B. Innis (2001). "Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers." Synapse **41**(4): 275-284.
22. Varrone, A., K. L. Marek, D. Jennings, R. B. Innis and J. P. Seibyl (2001). "[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy." Mov Disord **16**(6): 1023-1032.
23. van Dyck, C. H., D. M. Quinlan, L. M. Cretella, J. K. Staley, R. T. Malison, R. M. Baldwin, J. P. Seibyl and R. B. Innis (2002). "Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder." Am J Psychiatry **159**(2): 309-312.
24. van Dyck, C. H., J. P. Seibyl, R. T. Malison, M. Laruelle, S. S. Zoghbi, R. M. Baldwin and R. B. Innis (2002). "Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries." Am J Geriatr Psychiatry **10**(1): 36-43.
25. Antonini, A., R. Benti, R. De Notaris, S. Tesei, A. Zecchinelli, G. Sacilotto, N. Meucci, M. Canesi, C. Mariani, G. Pezzoli and P. Gerundini (2003). "123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy." Neurol Sci **24**(3): 149-150.
26. Kugaya, A., N. M. Seneca, P. J. Snyder, S. A. Williams, R. T. Malison, R. M. Baldwin, J. P. Seibyl and R. B. Innis (2003). "Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration." Neuropsychopharmacology **28**(2): 413-420.
27. Remy, P., Z. Malek and E. Itti (2003). "[123I-Ioflupane brain scintigraphy (DaTScan) to demonstrate loss of nigrostratal dopaminergic neurons: principles and applications]." Rev Neurol (Paris) **159**(10 Pt 1): 942-946.
28. Jennings, D. L., J. P. Seibyl, D. Oakes, S. Eberly, J. Murphy and K. Marek (2004). "(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis." Arch Neurol **61**(8): 1224-1229.
29. Kugaya, A., G. Sanacora, J. K. Staley, R. T. Malison, A. Bozkurt, S. Khan, A. Anand, C. H. Van Dyck, R. M. Baldwin, J. P. Seibyl, D. Charney and R. B. Innis (2004). "Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors." Biol Psychiatry **56**(7): 497-502.
30. van Dyck, C. H., R. T. Malison, J. K. Staley, L. K. Jacobsen, J. P. Seibyl, M. Laruelle, R. M. Baldwin, R. B. Innis and J. Gelernter (2004). "Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype." Am J Psychiatry **161**(3): 525-531.
31. Best, S. E., P. M. Sarrel, R. T. Malison, M. Laruelle, S. S. Zoghbi, R. M. Baldwin, J. P. Seibyl, R. B. Innis and C. H. van Dyck (2005). "Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle." Psychopharmacology (Berl) **183**(2): 181-189.
32. Ravina, B., D. Eidelberg, J. E. Ahlskog, R. L. Albin, D. J. Brooks, M. Carbon, V. Dhawan, A. Feigin, S. Fahn, M. Guttman, K. Gwinn-Hardy, H. McFarland, R. Innis, R. G. Katz, K. Kieburtz, S. J. Kish, N. Lange, J. W. Langston, K. Marek, L. Morin, C. Moy, D. Murphy, W. H. Oertel, G. Oliver, Y. Palesch, W. Powers, J. Seibyl, K. D. Sethi, C. W. Shults, P. Sheehy, A. J. Stoessl and R. Holloway (2005). "The role of radiotracer imaging in Parkinson disease." Neurology **64**(2): 208-215.
33. van Dyck, C. H., R. T. Malison, L. K. Jacobsen, J. P. Seibyl, J. K. Staley, M. Laruelle, R. M. Baldwin, R. B. Innis and J. Gelernter (2005). "Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene." J Nucl Med **46**(5): 745-751.
34. Isaias, I. U., R. Benti, S. Goldwurm, M. Zini, R. Cilia, P. Gerundini, A. Di Fonzo, V. Bonifati, G. Pezzoli and A. Antonini (2006). "Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation." Mov Disord **21**(8): 1144-1147.
35. Staley, J. K., G. Sanacora, G. Tamagnan, P. K. Maciejewski, R. T. Malison, R. M. Berman, M. Vythilingam, A. Kugaya, R. M. Baldwin, J. P. Seibyl, D. Charney and R. B. Innis (2006). "Sex differences in diencephalon serotonin transporter availability in major depression." Biol Psychiatry **59**(1): 40-47.
36. Canesi, M., R. Benti, G. Marotta, R. Cilia, I. U. Isaias, P. Gerundini, G. Pezzoli and A. Antonini (2007). "Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure." Eur J Neurol **14**(3): 297-299.
37. Shang, Y., M. A. Gibbs, G. J. Marek, T. Stiger, A. H. Burstein, K. Marek, J. P. Seibyl and J. F. Rogers (2007). "Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study." J Clin Psychopharmacol **27**(1): 71-75.
38. Isaias, I. U., M. Canesi, R. Benti, P. Gerundini, R. Cilia, G. Pezzoli and A. Antonini (2008). "Striatal dopamine transporter abnormalities in patients with essential tremor." Nucl Med Commun **29**(4): 349-353.
39. van Dyck, C. H., R. A. Avery, M. G. MacAvoy, K. L. Marek, D. M. Quinlan, R. M. Baldwin, J. P. Seibyl, R. B. Innis and A. F. Arnsten (2008). "Striatal dopamine transporters correlate with simple reaction time in elderly subjects." Neurobiol Aging **29**(8): 1237-1246.
40. Cosgrove, K. P., E. Krantzler, E. B. Frohlich, S. Stiklus, B. Pittman, G. D. Tamagnan, R. M. Baldwin, F. Bois, J. P. Seibyl, J. H. Krystal, S. S. O'Malley and J. K. Staley (2009). "Dopamine and serotonin transporter availability during acute alcohol withdrawal: effects of comorbid tobacco smoking." Neuropsychopharmacology **34**(10): 2218-2226.
41. Cosgrove, K. P., K. Tellez-Jacques, B. Pittman, I. Petrakis, R. M. Baldwin, G. Tamagnan, J. Seibyl, T. Kosten and J. K. Staley (2010). "Dopamine and serotonin transporter availability in chronic heroin users: a [(1)(2)(3)I]beta-CIT SPECT imaging study." Psychiatry Res **184**(3): 192-195.
42. Del Sole, A., V. Chiesa, G. Lucignani, A. Vignoli, L. Giordano, M. Lecchi and M. P. Canevini (2010). "Exploring dopaminergic activity in ring chromosome 20 syndrome: a SPECT study." Q J Nucl Med Mol Imaging.
43. Hall, D. A., D. Jennings, J. Seibyl, F. Tassone and K. Marek (2010). "FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients." Parkinsonism Relat Disord **16**(9): 608-611.
44. Seegal, R. F., K. L. Marek, J. P. Seibyl, D. L. Jennings, E. S. Molho, D. S. Higgins, S. A. Factor, E. F. Fitzgerald, E. A. Hills, S. A. Korrick, M. S. Wolff, R. F. Haase, A. C. Todd, P. Parsons and R. J. McCaffrey (2010). "Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study." Neurobiol Dis **38**(2): 219-225.
45. Parkinson Progression Marker, I. (2011). "The Parkinson Progression Marker Initiative (PPMI)." Prog Neurobiol **95**(4): 629-635.
46. Djang, D. S., M. J. Janssen, N. Bohnen, J. Booij, T. A. Henderson, K. Herholz, S. Minoshima, C. C. Rowe, O. Sabri, J. Seibyl, B. N. Van Berckel and M. Wanner (2012). "SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0." J Nucl Med **53**(1): 154-163.
47. Gerasimou, G., D. C. Costa, E. Papanastasiou, S. Bostanjiopoulou, M. Arnaoutoglou, E. Moralidis, T. Aggelopoulou and A. Gotzamani-Psarrakou (2012). "SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease?" Ann Nucl Med **26**(4): 337-344.
48. Haller, S., S. Badoud, D. Nguyen, V. Garibotto, K. O. Lovblad and P. R. Burkhard (2012). "Individual detection of patients with Parkinson disease using support vector machine analysis of diffusion tensor imaging data: initial results." AJNR Am J Neuroradiol **33**(11): 2123-2128.
49. Shtilbans, A. and C. Henchcliffe (2012). "Biomarkers in Parkinson's disease: an update." Curr Opin Neurol **25**(4): 460-465.
50. Bajaj, N., R. A. Hauser and I. D. Grachev (2013). "Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes." J Neurol Neurosurg Psychiatry **84**(11): 1288-1295.
51. Haller, S., S. Badoud, D. Nguyen, I. Barnaure, M. L. Montandon, K. O. Lovblad and P. R. Burkhard (2013). "Differentiation between Parkinson disease and other forms of Parkinsonism using support vector machine analysis of susceptibility-weighted imaging (SWI): initial results." Eur Radiol **23**(1): 12-19.
52. Bajaj, N., R. A. Hauser, J. Seibyl, A. Kupsch, M. Plotkin, C. Chen and I. D. Grachev (2014). "Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN) in subjects with clinically uncertain parkinsonian syndromes." Alzheimers Res Ther **6**(5-8): 67.
53. Cheng, G. and J. F. Morley (2014). "Complete and readily reversible blocking of striatal DaTscan binding by methylphenidate." Clin Nucl Med **39**(2): 211-213.
54. Jennings, D., A. Siderowf, M. Stern, J. Seibyl, S. Eberly, D. Oakes, K. Marek and P. Investigators (2014). "Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study." Neurology **83**(19): 1739-1746.
55. Marek, K., J. Seibyl, S. Eberly, D. Oakes, I. Shoulson, A. E. Lang, C. Hyson, D. Jennings and P. I. Parkinson Study Group (2014). "Longitudinal follow-up of SWEDD subjects in the PRECEPT Study." Neurology **82**(20): 1791-1797.
56. Matesan, M. C., D. J. Cross, D. H. Lewis and S. Minoshima (2015). "Differential alterations of dopamine transporter in the striatum and midbrain in patients with parkinsonian syndrome." Clin Nucl Med **40**(3): 191-194.
57. Matesan, M. C., D. J. Cross, D. H. Lewis and S. Minoshima (2015). "Differential alterations of dopamine transporter in the striatum and midbrain in patients with parkinsonian syndrome." Clin Nucl Med **40**(3): 191-194.
58. Skanjeti, A., G. Castellano, B. O. Elia, M. Zotta, F. Dazzara, M. Manfredi, A. Galati, S. Grimaldi, M. Balma, R. E. Pellerito and V. Podio (2015). "Multicenter Semiquantitative Evaluation of (123)I-FP-CIT Brain SPECT." J Neuroimaging **25**(6): 1023-1029.
59. Walker, Z., E. Moreno, A. Thomas, F. Inglis, N. Tabet, M. Rainer, G. Pizzolato, A. Padovani and T. D. L. B. P. S. G. Da (2015). "Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study." Br J Psychiatry **206**(2): 145-152.
60. Roussakis, A. A., M. Politis, D. Towey and P. Piccini (2016). "Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias." Neurology.

**Image analysis**

1. Nobili, F., C. Campus, D. Arnaldi, F. De Carli, G. Cabassi, A. Brugnolo, B. Dessi, S. Morbelli, G. Sambuceti, G. Abbruzzese and G. Rodriguez (2010). "Cognitive-nigrostriatal relationships in de novo, drug-naive Parkinson's disease patients: a [I-123]FP-CIT SPECT study." Mov Disord **25**(1): 35-43.
2. Illan, I. A., J. M. Gorrz, J. Ramirez, F. Segovia, J. M. Jimenez-Hoyuela and S. J. Ortega Lozano (2012). "Automatic assistance to Parkinson's disease diagnosis in DaTSCAN SPECT imaging." Med Phys **39**(10): 5971-5980.
3. Segovia, F., J. M. Gorriz, J. Ramirez, I. Alvarez, J. M. Jimenez-Hoyuela and S. J. Ortega (2012). "Improved parkinsonism diagnosis using a partial least squares based approach." Med Phys **39**(7): 4395-4403.
4. Brahim, A., J. M. Gorriz, J. Ramirez and L. Khedher (2014). "Linear intensity normalization of DaTSCAN images using Mean Square Error and a model-based clustering approach." Stud Health Technol Inform **207**: 251-260.
5. Kupitz, D., I. Apostolova, C. Lange, G. Ulrich, H. Amthauer, W. Brenner and R. Buchert (2014). "Global scaling for semi-quantitative analysis in FP-CIT SPECT." Nuklearmedizin **53**(6): 234-241.
6. Martinez-Murcia, F. J., J. M. Gorriz, J. Ramirez, M. Moreno-Caballero and M. Gomez-Rio (2014). "Parametrization of textural patterns in 123I-ioflupane imaging for the automatic detection of Parkinsonism." Med Phys **41**(1): 012502.
7. Menendez-Gonzalez, M., F. Tavares, N. Zeidan, J. M. Salas-Pacheco and O. Arias-Carrion (2014). "Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study." Front Aging Neurosci **6**: 56.
8. Padilla, P., J. Ramirez, J. M. Gorriz, D. Salas-Gonzalez, I. Alvarez-Illan and I. Parkinson's Progression Markers (2014). "Statistical significance in the selection of the regions of interest for Parkinson brain image processing." Stud Health Technol Inform **207**: 19-26.
9. Palumbo, B., M. L. Fravolini, T. Buresta, F. Pompili, N. Forini, P. Nigro, P. Calabresi and N. Tambasco (2014). "Diagnostic accuracy of Parkinson disease by support vector machine (SVM) analysis of 123I-FP-CIT brain SPECT data: implications of putaminal findings and age." Medicine (Baltimore) **93**(27): e228.
10. Brahim, A., J. Ramirez, J. M. Gorriz, L. Khedher and D. Salas-Gonzalez (2015). "Correction: Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism." PLoS One **10**(7): e0135107.
11. Brahim, A., J. Ramirez, J. M. Gorriz, L. Khedher and D. Salas-Gonzalez (2015). "Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism." PLoS One **10**(6): e0130274.

**Software**

1. Zubal, I. G., M. Early, O. Yuan, D. Jennings, K. Marek and J. P. Seibyl (2007). "Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients." J Nucl Med **48**(6): 857-864.
2. Kuo, P. H., R. Avery, E. Krupinski, H. Lei, A. Bauer, S. Sherman, N. McMillan, J. Seibyl and G. Zubal (2013). "Receiver-operating-characteristic analysis of an automated program for analyzing striatal uptake of 123I-ioflupane SPECT images: calibration using visual reads." J Nucl Med Technol **41**(1): 26-31.
3. Kuo, P. H., H. H. Lei, R. Avery, E. A. Krupinski, A. Bauer, S. Sherman, N. McMillan, J. Seibyl and G. I. Zubal (2014). "Evaluation of an Objective Striatal Analysis Program for Determining Laterality in Uptake of 123I-Ioflupane SPECT Images: Comparison to Clinical Symptoms and to Visual Reads." J Nucl Med Technol **42**(2): 105-108.
4. Oliveira, F. P. and M. Castelo-Branco (2015). "Computer-aided diagnosis of Parkinson's disease based on [(123)I]FP-CIT SPECT binding potential images, using the voxels-as-features approach and support vector machines." J Neural Eng **12**(2): 026008.